U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H14F3N5O
Molecular Weight 349.3111
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VORICONAZOLE

SMILES

C[C@@]([H])(c1c(cncn1)F)[C@](Cn2cncn2)(c3ccc(cc3F)F)O

InChI

InChIKey=BCEHBSKCWLPMDN-MGPLVRAMSA-N
InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00582

Voriconazole (vor-i-KON-a-zole, brand name Vfend, Pfizer) is a triazole antifungal medication. VFEND® (voriconazole) is available as film-coated tablets for oral administration, and as a lyophilized powder for solution for intravenous infusion. Voriconazole is a triazole antifungal agent indicated for use in the treatment of fungal infections including invasive aspergillosis, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani. Fungal plasma membranes are similar to mammalian plasma membranes, differing in having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane permeability changes and inhibition of growth. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems. The most common side effects associated with voriconazole include transient visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, peripheral edema, abdominal pain, and respiratory disorder. Unlike most adverse effects, which are similar to other azole antifungal agents, visual disturbances (such as blurred vision or increased sensitivity to light) are unique to voriconazole. Though rare, there have been cases of serious hepatic reactions during treatment with voriconazole (a class effect of azole antifungal agents). Liver function tests should be evaluated at the start of and during the course of therapy. Voriconazole is phototoxic. It has been associated with an increased risk of squamous-cell carcinoma of the skin

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

1.07084159E12
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

1.07084159E12
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

1.07084159E12
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

1.07084159E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.13 μg/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.31 μg/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.03 μg/mL
3 mg/kg 2 times / day steady-state, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.77 μg/mL
4 mg/kg 2 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.74 μg/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.3 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.1 μg/mL
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13.9 μg × h/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.4 μg × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
13.7 μg × h/mL
3 mg/kg 2 times / day steady-state, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
33.9 μg × h/mL
4 mg/kg 2 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
34 μg × h/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9.31 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
27.9 μg × h/mL
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.5 h
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
42%
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
42%
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Photophobia, Fatigue...
AEs leading to
discontinuation/dose reduction:
Photophobia (1 patient)
Fatigue (1 patient)
Concentration impaired (1 patient)
Insomnia (1 patient)
Sources:
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Disc. AE: Function liver abnormal, Hallucination, visual...
AEs leading to
discontinuation/dose reduction:
Function liver abnormal (73 patients)
Hallucination, visual (16 patients)
Skin rash (6 patients)
Kidney dysfunction (3 patients)
Electrocardiogram QTc interval prolonged (2 patients)
Gastrointestinal symptom NOS (1 patient)
Sources:
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 53.4–67.5 years
n = 31
Health Status: unhealthy
Condition: Acute myeloid leukemia, Acute lymphoid leukemia, Lymphoma, Others
Age Group: 53.4–67.5 years
Sex: M+F
Population Size: 31
Sources:
Disc. AE: CRP increased, Bilirubin increased...
AEs leading to
discontinuation/dose reduction:
CRP increased (31 patient)
Bilirubin increased (31 patient)
Sources:
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and invasive aspergillosis
Age Group: 9 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Photophobia...
AEs leading to
discontinuation/dose reduction:
Photophobia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Concentration impaired 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Fatigue 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Insomnia 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Photophobia 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and allergic bronchopulmonary aspergillosis
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Gastrointestinal symptom NOS 1 patient
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Hallucination, visual 16 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Electrocardiogram QTc interval prolonged 2 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Kidney dysfunction 3 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Skin rash 6 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Function liver abnormal 73 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
n = 327
Health Status: unhealthy
Condition: Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other
Age Group: 42.7–64.5 years
Sex: M+F
Population Size: 327
Sources:
Bilirubin increased 31 patient
Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 53.4–67.5 years
n = 31
Health Status: unhealthy
Condition: Acute myeloid leukemia, Acute lymphoid leukemia, Lymphoma, Others
Age Group: 53.4–67.5 years
Sex: M+F
Population Size: 31
Sources:
CRP increased 31 patient
Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 53.4–67.5 years
n = 31
Health Status: unhealthy
Condition: Acute myeloid leukemia, Acute lymphoid leukemia, Lymphoma, Others
Age Group: 53.4–67.5 years
Sex: M+F
Population Size: 31
Sources:
Photophobia 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
n = 1
Health Status: unhealthy
Condition: cystic fibrosis and invasive aspergillosis
Age Group: 9 years
Sex: M
Population Size: 1
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96% and fluconazole increased voriconazole Cmax by 57% and AUC 79%
Page: 2, 10,13, 21-23, 26-27
no
no
no
yes [Km 21 uM]
yes (co-administration study)
Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96%; fluconazole increased voriconazole Cmax by 57% and AUC 79%
Page: 11.0
yes [Km 240 uM]
yes (co-administration study)
Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96%; fluconazole increased voriconazole Cmax by 57% and AUC 79%
Page: 11.0
PubMed

PubMed

TitleDatePubMed
[Therapy of invasive organ mycoses in patients with systemic hematologic diseases].
2001
Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis.
2001
Coccidioidomycosis: efficacy of new agents and future prospects.
2001 Dec
In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole.
2001 Dec
Antifungal activity of the new azole UK-109 496 (voriconazole): addition and clarification.
2001 Nov
Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.
2001 Nov
Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
2001 Nov 23
Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategies.
2002
Pharmacological aspects of the new triazole voriconazole.
2002
Successful treatment of Candida glabrata myocarditis with voriconazole.
2002
Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole.
2002
Influence of voriconazole and fluconazole on Candida albicans in long-time continuous flow culture.
2002
Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia.
2002 Apr
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
2002 Apr
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
2002 Aug 8
Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
2002 Dec
Usefulness of a colorimetric method for testing antifungal drug susceptibilities of Aspergillus species to voriconazole.
2002 Dec
Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.
2002 Dec
Case Reports. Chronic and acute Aspergillus meningitis.
2002 Dec
Voriconazole versus amphotericin B for invasive aspergillosis.
2002 Dec 19
Voriconazole versus amphotericin B for invasive aspergillosis.
2002 Dec 19
Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans.
2002 Feb
The 2001 Garrod lecture. The treatment of cytomegalovirus infection.
2002 Feb
Azole cross-resistance in Aspergillus fumigatus.
2002 Feb
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
2002 Jan 24
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
2002 Jul
Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment.
2002 Jul
E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.
2002 Jun
Voriconazole and fluconazole susceptibility of Candida isolates.
2002 Jun
New drugs, old drugs - dear drugs, cheap drugs.
2002 Jun 15
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
2002 May 30
Voriconazole -- better chances for patients with invasive mycoses.
2002 May 31
Management of mycoses in patients with hematologic disease and cancer -- review of the literature.
2002 May 31
Decisions about voriconazole versus liposomal amphotericin B.
2002 May 9
Gateways to clinical trials.
2002 Nov
In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).
2002 Nov
An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis.
2002 Nov 1
The safety of voriconazole.
2002 Nov 15
Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature.
2002 Sep
Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil.
2002 Sep
Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry.
2002 Sep 5
Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii.
2003 Aug
Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine.
2003 Feb
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
2003 Feb
Antifungal pharmacotherapy for invasive mould infections.
2003 Feb
Disseminated infection due to Cylindrocarpon (Fusarium) lichenicola in a neutropenic patient with acute leukaemia: report of a case and review of the literature.
2003 Jan
Activity of voriconazole against corneal isolates of Scedosporium apiospermum.
2003 Jan
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
2003 Jan
Arthritis and osteomyelitis due to Aspergillus fumigatus: a 17 years old boy with chronic granulomatous disease.
2003 Jan 31
Voriconazole: a new triazole antifungal agent.
2003 Mar 1
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: I.V. for Injection requires reconstitution to 10 mg/mL and subsequent dilution to 5 mg/mL or less prior to administration as an infusion, at a maximum rate of 3 mg/kg per hour over 1-2 hours
Tablets should be taken at least one hour before, or one hour following, a meal.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: The in vitro data obtained suggest that voriconazole may be effective in the treatment of opportunistic fungal infections.These investigators also noted that voriconazole was significantly more effective than itraconazole in reducing Aspergillus content in the lungs of immunocompromised animals with pulmonary aspergillosis.
each microdilution well containing 100 ul of the drug concentrations was inoculated with 100 ul of the diluted inoculum suspension (final volume in each well was 200 ul). Drug concentrations were 0.03 to 16 mg/ml for voriconazole. Stock inoculum suspensions of the molds were prepared from 7-day (Aspergillus spp., Bipolaris spp., P. boydii, R. arrhizus, and S. schenckii) or 7- to 10-day (B. dermatitidis and H. capsulatum) cultures grown on PDA at 35°C (cultures for Fusarium spp. were grown at 35°C for 48 to 72 h and then at 25 to 28°C until day 7
Name Type Language
VORICONAZOLE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
4-PYRIMIDINEETHANOL, A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-, (.ALPHA.R,.BETA.S)-
Common Name English
VORICONAZOLE [ORANGE BOOK]
Common Name English
UK-109,496
Code English
VORICONAZOLE [INN]
Common Name English
UK-109496
Code English
(.ALPHA.R,.BETA.S)-A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-4-PYRIMIDINEETHANOL
Common Name English
VORICONAZOLE [JAN]
Common Name English
VORICONAZOLE [WHO-DD]
Common Name English
VORICONAZOLE [USP-RS]
Common Name English
VFEND
Brand Name English
NSC-759888
Code English
VORICONAZOLE [MART.]
Common Name English
VORICONAZOLE [EMA EPAR]
Common Name English
VORICONAZOLE [MI]
Common Name English
VORICONAZOLE [USAN]
Common Name English
VORICONAZOLE [EP MONOGRAPH]
Common Name English
VORICONAZOLE [USP MONOGRAPH]
Common Name English
VORICONAZOLE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C514
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
NDF-RT N0000008217
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
WHO-ATC J02AC03
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
WHO-VATC QJ02AC03
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
NDF-RT N0000175487
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
LIVERTOX 1039
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
Code System Code Type Description
RXCUI
121243
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY RxNorm
MESH
C102790
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
DRUG BANK
DB00582
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
NDF-RT
N0000182140
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
EVMPD
SUB00087MIG
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
ChEMBL
CHEMBL638
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
CAS
137234-62-9
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
EPA CompTox
137234-62-9
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
MERCK INDEX
M11501
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C1707
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
INN
7269
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
NDF-RT
N0000185504
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
USP_CATALOG
1718008
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY USP-RS
FDA UNII
JFU09I87TR
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
PUBCHEM
71616
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
DRUG CENTRAL
2846
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
NDF-RT
N0000182141
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]